842 related articles for article (PubMed ID: 19098844)
1. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen.
Rokkas T; Sechopoulos P; Robotis I; Margantinis G; Pistiolas D
Am J Gastroenterol; 2009 Jan; 104(1):21-5. PubMed ID: 19098844
[TBL] [Abstract][Full Text] [Related]
2. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
[TBL] [Abstract][Full Text] [Related]
3. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
Uygun A; Kadayifci A; Safali M; Ilgan S; Bagci S
J Dig Dis; 2007 Nov; 8(4):211-5. PubMed ID: 17970879
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori Infection in the Japanese population: a multicenter study in the Tokyo Metropolitan Area.
Matsuhisa T; Kawai T; Masaoka T; Suzuki H; Ito M; Kawamura Y; Tokunaga K; Suzuki M; Mine T; Takahashi S; Sakaki N
Helicobacter; 2006 Jun; 11(3):152-8. PubMed ID: 16684262
[TBL] [Abstract][Full Text] [Related]
6. [Eradication of Helicobacter pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2002].
Buzás GM; Józan J
Orv Hetil; 2004 Oct; 145(40):2035-41. PubMed ID: 15559530
[TBL] [Abstract][Full Text] [Related]
7. Empirical Helicobacter pylori "rescue" therapy after failure of two eradication treatments.
Gisbert JP; Gisbert JL; Marcos S; Pajares JM
Dig Liver Dis; 2004 Jan; 36(1):7-12. PubMed ID: 14971810
[TBL] [Abstract][Full Text] [Related]
8. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection.
Cammarota G; Martino A; Pirozzi G; Cianci R; Branca G; Nista EC; Cazzato A; Cannizzaro O; Miele L; Grieco A; Gasbarrini A; Gasbarrini G
Aliment Pharmacol Ther; 2004 Apr; 19(7):789-95. PubMed ID: 15043520
[TBL] [Abstract][Full Text] [Related]
9. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
Nista EC; Candelli M; Zocco MA; Cremonini F; Ojetti V; Finizio R; Spada C; Cammarota G; Gasbarrini G; Gasbarrini A
Am J Gastroenterol; 2006 Sep; 101(9):1985-90. PubMed ID: 16968503
[TBL] [Abstract][Full Text] [Related]
10. Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens.
Filipec Kanizaj T; Katicic M; Skurla B; Ticak M; Plecko V; Kalenic S
Helicobacter; 2009 Feb; 14(1):29-35. PubMed ID: 19191893
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of Helicobacter pylori eradication rates of twice-versus four-times-daily amoxicillin administered with proton pump inhibitor and clarithromycin: a randomized study.
Kim SY; Lee SW; Jung SW; Koo JS; Yim HJ; Park JJ; Chun HJ; Lee HS; Choi JH; Kim CD; Ryu HS
Helicobacter; 2008 Aug; 13(4):282-7. PubMed ID: 18665938
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication.
Akyildiz M; Akay S; Musoglu A; Tuncyurek M; Aydin A
Eur J Intern Med; 2009 Jan; 20(1):53-7. PubMed ID: 19237093
[TBL] [Abstract][Full Text] [Related]
13. Levofloxacin- vs. ranitidine bismuth citrate-containing therapy after H. pylori treatment failure.
Gisbert JP; Gisbert JL; Marcos S; Moreno-Otero R; Pajares JM
Helicobacter; 2007 Feb; 12(1):68-73. PubMed ID: 17241304
[TBL] [Abstract][Full Text] [Related]
14. Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.
Chung SJ; Lee DH; Kim N; Jung SH; Kim JW; Hwang JH; Park YS; Lee KH; Jung HC; Song IS
Hepatogastroenterology; 2007 Jun; 54(76):1293-6. PubMed ID: 17629092
[TBL] [Abstract][Full Text] [Related]
15. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.
Wong WM; Gu Q; Chu KM; Yee YK; Fung FM; Tong TS; Chan AO; Lai KC; Chan CK; Wong BC
Aliment Pharmacol Ther; 2006 Feb; 23(3):421-7. PubMed ID: 16423001
[TBL] [Abstract][Full Text] [Related]
16. How to proceed in Helicobacter pylori-positive chronic gastritis refractory to first- and second-line eradication therapy.
Vaira D; Ricci C; Lanzini A; Perna F; Romano A; Corinaldesi R
Dig Dis; 2007; 25(3):203-5. PubMed ID: 17827940
[TBL] [Abstract][Full Text] [Related]
17. Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial.
Francavilla R; Lionetti E; Castellaneta SP; Magistà AM; Boscarelli G; Piscitelli D; Amoruso A; Di Leo A; Miniello VL; Francavilla A; Cavallo L; Ierardi E
Gastroenterology; 2005 Nov; 129(5):1414-9. PubMed ID: 16285942
[TBL] [Abstract][Full Text] [Related]
18. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures.
Gisbert JP; Gisbert JL; Marcos S; Moreno-Otero R; Pajares JM
Aliment Pharmacol Ther; 2006 Nov; 24(10):1469-74. PubMed ID: 17032282
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.
Marko D; Calvet X; Ducons J; Guardiola J; Tito L; Bory F;
Helicobacter; 2005 Feb; 10(1):22-32. PubMed ID: 15691312
[TBL] [Abstract][Full Text] [Related]
20. [Ilaprazole based bismuth-containing quadruple regimen for the first-line treatment of Helicobacter pylori infection: a multicenter, randomized, controlled clinical study].
Gao W; Cheng H; Hu FL; Lü NH; Xie Y; Sheng JQ; Xu JM; Zhang LX; Zhang L; Chen Y; Zhang ZY; Zhang GX; Cui MH; Yang GB; Gao HJ; Yang L
Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(30):2108-12. PubMed ID: 23158273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
